 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for January 30, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| KLDO | Hot Stocks20:45 EST Kaleido Biosciences to halt work on planned Phase 2 COPD study - In a regulatory filing after the close on Friday, Kaleido Biosciences disclosed that the company has decided to halt work on a planned Phase 2 chronic obstructive pulmonary disease, or COPD, study and terminate its agreement with the COPD Foundation. "These decisions were made in order to re-align resources and focus the company's efforts," Kaleido stated.
|
| CTXS... | Hot Stocks20:04 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Citrix Systems (CTXS) is close to a deal to be taken private, continuing a spate of big leveraged buyouts, The Wall Street Journal's Cara Lombardo reported. Elliott Management's private-equity arm, Evergreen Coast Capital, and Vista Equity Partners are near an agreement to pay $104 a share, or roughly $13 billion, for the software company, the author noted, citing people familiar with the matter. The deal could be announced Monday, the sources said. 2. Walgreens Boots Alliance (WBA) has kicked off the sales process for its Boots international drugstore unit as fresh buyout companies, including Sycamore Partners, consider bids, Bloomberg's Aaron Kirchfeld, Dinesh Nair, and Jan-Henrik Foerster report, citing people familiar with the matter. The U.S. company is sending out preliminary information on the business to potential suitors ahead of first-round bids due in the coming weeks, the sources said. Boots, which mostly operates pharmacies in Britain, could be valued at as much as $9.6B in a sale, Bloomberg said. 3. Tesla (TSLA) shares got hammered this past week after the company reported better-than-expected fourth quarter earnings, with the reaction to record profits and an earnings beat leaving investors as well as analysts dazed and confused, Al Root wrote in this week's edition of Barron's. It's the third-worst reaction to any Tesla quarter over the past 11 years, but the other two made more sense because portions of the reported results missed analyst expectations, the author noted. This coming week brings earnings reports from Ford (F) and General Motors (GM), and investors will be watching for how they navigate the chip shortages. Tesla stock, surprisingly, looks like the best bet over the coming months, as chip supplies and 2022 outlooks work themselves out, Root argued. While Tesla shares now trade for about 83 times estimated 2022 earnings - a high multiple -, it also grows the fastest of the bunch by a long shot, the publication added. 4. Sony (SONY) and Marvel's "Spider-Man: No Way Home" won this weekend's box office in its seventh outing as moviegoing continued to slow amid surge in COVID cases due to the omicron variant. The super hero movie earned $11M for a domestic total of $735M, the fourth best showing of all time, not adjusted for inflation. Overseas, "No Way Home" surpassed the $1B mark, siting at $1.74B, the sixth best of all time. 5. Wesco (WCC) and Moderna (MRNA) saw positive mentions in this week's edition of Barron's.
|
| SPOT | Hot Stocks16:03 EST Spotify publishes content policy in response to Rogan controversy - Spotify's chief executive Daniel Ek said in a blog post that, "To our very core, we believe that listening is everything. Pick almost any issue and you will find people and opinions on either side of it. Personally, there are plenty of individuals and views on Spotify that I disagree with strongly. We know we have a critical role to play in supporting creator expression while balancing it with the safety of our users. In that role, it is important to me that we don't take on the position of being content censor while also making sure that there are rules in place and consequences for those who violate them. You've had a lot of questions over the last few days about our platform policies and the lines we have drawn between what is acceptable and what is not. We have had rules in place for many years but admittedly, we haven't been transparent around the policies that guide our content more broadly. This, in turn, led to questions around their application to serious issues including COVID-19. Based on the feedback over the last several weeks, it's become clear to me that we have an obligation to do more to provide balance and access to widely-accepted information from the medical and scientific communities guiding us through this unprecedented time. These issues are incredibly complex. We've heard you - especially those from the medical and scientific communities - and are taking the following steps: Today we are publishing our long-standing Platform Rules... We are working to add a content advisory to any podcast episode that includes a discussion about COVID-19... We will also begin testing ways to highlight our Platform Rules in our creator and publisher tools to raise awareness around what's acceptable and help creators understand their accountability for the content they post on our platform." Reference Link
|
